Literature DB >> 1440180

Current clinical and pathologic perspectives on gastric stromal tumors.

M D Basson1, I M Modlin, S D Flynn.   

Abstract

Gastric stromal tumors are heterogeneous and poorly understood. Investigators have studied these tumors by histologic and immunocytochemical characteristics, but interlaboratory variations have impeded clinical application of these techniques. Although many gastric stromal tumors can be categorized as benign or malignant with some certainty, occasional instances may present great difficulty in this distinction. Uncertainty about malignant potential and the biologic factors of the lesion will therefore generally suggest excision with a 1 to 2 centimeter margin for diagnosis and definitive therapy of these tumors. Subsequent prognosis will be dictated primarily by tumor size, histologic factors and mitotic index. Gastric stromal tumors in young women should suggest the possibility of Carney's triad. Functional extra-adrenal paragangliomas and pulmonary chondromas should be sought preoperatively. The paraganglioma should be managed first and the gastric lesion then addressed. Distal gastrectomy of at least 50 percent would seem to represent a reasonable resection limit. Identification of the specific cellular biologic factors of these lesions will be necessary to accurately classify particular tumors, gauge prognosis and individualize their management.

Entities:  

Mesh:

Year:  1992        PMID: 1440180

Source DB:  PubMed          Journal:  Surg Gynecol Obstet        ISSN: 0039-6087


  2 in total

1.  Gastric stromal tumours: a practical approach.

Authors:  N Mihssin; K Moorthy; A Sengupta; P W Houghton
Journal:  Ann R Coll Surg Engl       Date:  2000-11       Impact factor: 1.891

2.  Expression of COX-2, PCNA, Ki-67 and p53 in gastrointestinal stromal tumors and its relationship with histopathological parameters.

Authors:  Derya Gumurdulu; Seyda Erdogan; Fazilet Kayaselcuk; Gulsah Seydaoglu; Cem-K Parsak; Orhan Demircan; Ilhan Tuncer
Journal:  World J Gastroenterol       Date:  2007-01-21       Impact factor: 5.742

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.